The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase III trials.
J. Treat
Employment or Leadership Position - Lilly
G. Scagliotti
Consultant or Advisory Role - Lilly
Honoraria - Lilly
G. Peng
Employment or Leadership Position - Lilly
M. J. Monberg
Employment or Leadership Position - Lilly
C. K. Obasaju
Employment or Leadership Position - Lilly